ѻý

<ѻý class="page-title">Meeting Coverage

ASH Video Pearls

<ѻý class="page-description">Video Pearls from the American Society of Hematology
Clonal Evolution of IDH2 Mutations in AML

Study examined evolution through AML disease course

image
<ѻý class="section_title">Latest ASH Video Pearls Meeting Coverage
Enriched CAR-T Shows Durable Responses in Multiple Myeloma

Melissa Alsina, MD, discusses the data on this anti-BCMA CAR T-cell therapy

February 22, 2021
Associating Baseline PROs and Complications of Stem Cell Transplant

Secondary analysis examined quality of life, fatigue, and depression

February 16, 2021
Using the Epigenetic Landscape to Define Myeloma

New database might help explain progression and resistance, says Rafael Renatino-Canevarolo, PhD

February 8, 2021
Talquetamab Shows Encouraging Responses in R/R Multiple Myeloma

Bispecific antibody passes first-in-human study

January 18, 2021
Emerging Therapies in Multiple Myeloma

Joseph Mikhael, MD, discusses the CAR-T cell therapy trials from ASH 2020

January 11, 2021
Identifying MDS in Patients With Myeloma

Next generation sequencing is playing an increasing role

December 16, 2020
Myeloma: CAR T-Cell Therapy Produces Deep and Durable Responses

Deepu Madduri, MD, discusses the CARTITUDE-1 trial

December 14, 2020
Impact of TP53 Mutation Clearance Prior to Allo-SCT

Study clarifies if clearance prior to transplantation could influence outcomes

February 27, 2020
Future of T-Cell Lymphoma Treatment

Owen O'Connor, MD, thinks we are ready to turn the corner with some novel combinations

January 16, 2020
B-ALL Patients Benefit From Blincyto

Joseph Jurcic, MD, on study showing more patients able to undergo transplant, surviving longer with less relapse

January 9, 2020
Venetoclax in Relapsed or Refractory Multiple Myeloma

Two abstracts were promising for patients with translocation 11;14

January 2, 2020